Drug firm Dr Reddy's Laboratories today announced the launch of Bispec tablets (solifencin succinate)

RELATED ARTICLES Sensex snaps two-day rally, down 82 pts on poor IIP nos Sensex up 123 pts in late buying amid firm European mkts Thomas Cook PLC starts process of stake sale in Indian arm Sensex closes 85 points up in volatile trade Sensex snaps 5 day rally on low growth estimates

used in the management of over active bladder.

"Bispec is the best in class for Over Active Bladders (OAB) and has lesser incidence of dry mouth and constipation," the company said in filing to the Bombay Stock Exchange (BSE).

People suffering from OAB have a warning time of about 12 seconds but with the help of solifencin succinate tablets, the warning time can be increased to around 32 seconds, the company said.

Warning time is the period between first sensation of urgency and urination for the patients suffering from OAB syndrome.

The drug reduces bladder contradictions and improves warning time in OAB patients, it added.

The company has launched the drug in tablet forms in two strengths, 5 mg and 10 mg, and the total market size of the product is around Rs 19.4 crore, which is growing at the rate of 7 % per annum.